跳至主要内容
临床试验/NCT05778656
NCT05778656已完成不适用

Cardiovascular Risk Prevention With a Mediterranean Dietary Pattern Reduced in Saturated Fat (CADIMED): Randomized Controlled Dietary Intervention Study With Metabolomic and Gut Microbiome Analyses

Universidad de Granada2 个研究点 分布在 1 个国家目标入组 157 人开始时间: 2023年3月19日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
157
试验地点
2
主要终点
LDL-Cholesterol (mg/dL)

研究概览

简要总结

The Cardiovascular Risk Prevention With a Mediterranean Dietary Pattern Reduced in Saturated Fat (CADIMED) study is a randomized, controlled intervention trial aiming to develop a dietary intervention that promotes saturated fat (SFA) reduction through eliminating red and processed meat consumption and to evaluate its impact on lipid and cardiovascular disease (CVD) risk biomarkers.

The main research question is:

* Does lowering SFA intake from specific foods (e.g., red and processed meat) modify cardiovascular risk factors in a Mediterranean dietary pattern context?

The aim is to compare, in a sample of 156 adult subjects (>18 years) with dyslipidemia, the effect of an intervention that promotes the elimination of red and processed meat intake vs. the control group that will follow the usual health advice for CVD prevention. Changes in CVD risk biomarkers, blood metabolomics and the microbiome will be investigated after 8 weeks of intervention.

详细描述

  1. BACKGROUND

Globally, cardiovascular diseases (CVD) are the leading cause of mortality. The World Health Organization estimates that, in 2019, 32% of deaths worldwide were due to CVD, mainly acute myocardial infarction. The most important cardiovascular risk factors are modifiable and are associated with poor diet, lack of physical activity, tobacco and alcohol consumption. Among them, it has been shown that an adequate diet is essential for the prevention of CVD given its effects on blood pressure, lipids, obesity, inflammation and endothelial function Amongst all dietary risk factors, saturated fatty acids (SFA) are of great interest because of their effects on low-density lipoprotein cholesterol (LDL-C) and total cholesterol, which are associated with increased cardiovascular risk due to endothelial dysfunction and atherosclerosis. Because of this, different organizations and institutions, such as the American Heart Association and the European Society of Cardiology, advise that SFA should represent less than 10% of total energy intake, preferably between 5% and 6% to prevent CVD. A Cochrane meta-analysis of clinical trials has shown that reducing SFA consumption decreases LDL-C significantly and up to 17% of cardiovascular events.

Current clinical practice guidelines on the prevention and treatment of CVD generally recommend a low-SFA healthy diet but do not offer detailed or specific advice for effective interventions. This is important as different food sources of SFA may have different health risks. Foods contain complex mixtures of SFA, and evidence suggests that some fatty acids, such as lauric, myristic, and palmitic acid, may pose different risks. In particular, red meat contains a high proportion of palmitic acid [long-chain SFA (16:0)] and, although the current evidence is inconsistent and mainly based on observational studies, an increased risk of CVD has been associated with a higher intake of red and processed meat compared to plant protein sources, probably mediated by changes in lipid profile, inflammation or insulin resistance. However, other SFA-rich foods, such as milk and cheese, contain high proportions of shorter-chain fatty acids [lauric (12:0) and myristic (14:0)] and have not shown an association with CVD. It has been suggested that dairy products have other elements, such as calcium, which may counteract the unfavorable physiological effects of SFA.

The principal investigator of this project has recently conducted an intervention study to reduce dietary SFA in a population at cardiovascular risk, which found a non-significant decrease in SFA intake. However, beneficial changes in blood lipid profile were observed among those participants who reduced their consumption of red and processed meats the most, compared to those who reduced other sources of SFA as dairy. In general, the current evidence is limited but suggests that different sources of SFA and individual proportions of SFA in red and processed meat may influence the cardiovascular profile differently; therefore robust intervention studies are required to confirm this. Also, changes in the fatty acid and blood lipid profile resulting from a dietary approach based on a Mediterranean dietary pattern without red and processed meat are widely unknown. It is relevant to investigate how these dietary modifications affect cardiovascular risk factors in the context of a Mediterranean diet in which consumption of unsaturated fats from olive oil or nuts confers benefits for CVD prevention.

On the other hand, despite recent public health efforts, the reduction of SFA consumption through education or information programs in the population has not been sufficient. Previous research has established that it is possible to reduce the intake of SFA-rich foods by providing foods that replace them, and/or through intensive and adapted eating advice, requiring specialized staff and behavioral support. However, there is limited evidence on the effectiveness of less intensive and lower-cost interventions that can reach a greater number of people and have a significant effect on the population. Simple dietary guidelines that target specific foods (e.g., red meat) that are related to cardiovascular risk may have a greater potential to be adopted by an increasing number of people who need help to improve their diet quality and thus decrease their cardiovascular risk.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Care Provider, Investigator, Outcomes Assessor)

盲法说明

A computer-generated randomization with a stratified block design will be used, with sex, age, obesity, and fiber intake as stratification variables using randomly permuted blocks of size 2 and 4. The computer program (RedCap) will reveal the group allocation to the researcher, with no option to visualize the groups that will be assigned to future patients.

It will not be possible to blind patients to the intervention group due to the nature of the intervention. However, the effectiveness measure comparing trial arms (primary outcomes) are objectively measured outcomes (blood lipids and metabolites) and not subject to interpretation by researchers, limiting the effect that researcher knowledge of the intervention group could have on outcomes. Where possible, the study team taking all the outcome measurements will remain blind to group allocation throughout the trial.

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed informed consent form.
  • Age ≥18 years to ≤75 years.
  • With indication to start lifestyle intervention based on recent values (e.g., last 3-6 months) of LDL-C ≥ 116 mg/dl and < 190 mg/dl; or as long as pharmacological treatment has not been advised and started (ESC/EAS Guide, Rev Esp Cardiol. 2020).
  • Access to a device (e.g., smartphone, tablet, computer) with internet and digital skills to use the website.
  • Motivation and willingness to be assigned to any group to improve their diet and commitment to perform the designated protocol.

排除标准

  • Patients with familial hypercholesterolemia and/or on treatment with lipid-lowering drugs (including statins, ezetimibe, PCSK9 inhibitors, fibrates, bile acid sequestrants, omega-3 fatty acids, nicotinic acid/Vit B3), dietary supplements or functional foods for the treatment of dyslipidemia (plant sterols, monacolin, red yeast rice, fiber supplements 3-10 g (Plantago), policosanol, berberine, and soy protein/lecithin) in the last 3 months.
  • High cardiovascular risk that requires pharmacological treatment, for example, patients with recent and/or established CVD, type 1 and 2 diabetes.
  • Uncompensated thyroid function disorders; relevant comorbidities (including liver failure and cholestasis, chronic kidney disease, Cushing's syndrome, nephrotic syndrome, class III obesity - BMI ≥ 40 kg/m²); cancer; psychiatric disorders and/or that in the opinion of the investigator hinder the fulfillment or follow-up of the study.
  • Excessive alcohol consumption: > 40 g/d (4 UBEs/day) in men and > 20-25 g/d (2-2.5 UBEs/day) in women (Ministry of Health, July 2020).
  • Pregnancy, lactation, perimenopause (amenorrhea < 1 year) and women who change, start, or finish their treatment with hormonal contraceptives during the study.
  • Enrollment in other research studies or following restricted eating patterns (e.g., vegetarians and vegans) that could interfere with study requirements.
  • Failure to grant informed consent or not complete the initial assessment.

结局指标

主要结局

LDL-Cholesterol (mg/dL)

时间窗: 8 weeks

To investigate changes in LDL-C after 8 weeks in the intervention group compared to control

Fatty acid profile (%)

时间窗: 8 weeks

The initial plan was to investigate changes in palmitic acid after 8 weeks in the intervention group compared to control. However, after careful consideration with experts in Biochemistry, it is proposed to measure the overall fatty acid profile in erytrocyte membranes (instead of measuring palmitic acid individually for the primary outcome and the rest of individual fatty acids for the secondary outcome measures). Given the nature of this dietary intervention and the homeostatic metabolic processes that regulate individual fatty acids, it is advised to look at changes in the overall fatty acid profile (ie. their relative proportion within the overall profile) in response to the intervention. This change does not affect any methodological aspect of the trial because the sample size was calculated based on the primary outcome LDL-cholesterol change (see Statistical Analysis in Study Description)

次要结局

  • Metabolites derived from lipid and metabolomic profile analysis (mg/dL)(8 weeks)
  • Metabolites derived from lipid and metabolomic profile analysis (percentage)(8 weeks)
  • CVD risk related markers: C-reactive protein, IL-6, IL8/CXCL8, IL10, IL23, TNF-alpha, IFNgamma, ICAM1, VCAM1, ELAM1, MPO, endotelin I, angiotensin II (ng/mL)(8 weeks)
  • CVD risk related markers: Glucose (mg/dL)(8 weeks)
  • CVD risk related markers: Insulin (mU/ml)(8 weeks)
  • CVD risk related markers: HbA1c (percentage)(8 weeks)
  • CVD risk related markers: systolic and diastolic blood pressure (mmHg)(8 weeks)
  • CVD risk related markers: weight (kg)(8 weeks)
  • CVD risk related markers: waist circumference (cm)(8 weeks)
  • Gut microbiome composition(8 weeks)
  • Gut microbiome derived metabolites(8 weeks)
  • Dietary intake: total daily energy intake (kcal)(8 weeks)
  • Dietary intake: meat consumption (gr)(8 weeks)
  • Dietary intake: meat consumption (kcal)(8 weeks)
  • Dietary intake: meat consumption (percentage of energy intake)(8 weeks)
  • Dietary intake: relevant macro and micronutrients (gr)(8 weeks)
  • Dietary intake: relevant macro and micronutrients (kcal)(8 weeks)
  • Dietary intake: relevant macro and micronutrients (percentage of energy)(8 weeks)
  • Dietary intake: dietary patterns (z score)(8 weeks)
  • Other lifestyle factors: physical activity (minutes)(8 weeks)
  • Other lifestyle factors: smoking (cigerettes/day)(8 weeks)
  • Other lifestyle factors: alcohol intake (units/day)(8 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Carmen Piernas Sanchez

Senior researcher

Universidad de Granada

研究点 (2)

Loading locations...

相似试验

Cardiovascular Risk Prevention With a Mediterranean... | 临床试验